Drugs - Xagena.net - Update in Medicine

Search results for "Abiraterone"

Zytiga: CHMP recommends to broaden indication to include the treatment of men with newly diagnosed high-risk metastatic hormone-sensitive prostate cancer

The EMA’s Committee for Medicinal Products for Human Use ( CHMP ) has recommended broadening the existing marketing authorisation for Zytiga ( Abiraterone acetate ) plus Prednisone / Prednisolone to i ... read article

Treatment of BRCA1/2 or ATM gene mutated metastatic castration resistant prostate cancer: Lynparza granted Breakthrough Therapy designation by FDA

The FDA ( Food and Drug Administration ) has granted Breakthrough Therapy designation ( BTD ) for the oral poly ADP-ribose polymerase ( PARP ) inhibitor Lynparza ( Olaparib ), for the monotherapy trea ... read article

Xtandi for prostate cancer recommended by NICE

People with hormone-relapsed prostate cancer that has spread to other parts of the body and have been treated with the cytotoxic drug Docetaxel, should be given access to Enzalutamide ( Xtandi ) throu ... read article

Zytiga for late-stage prostate cancer, FDA approves

The FDA ( Food and Drug Administration ) has approved Zytiga ( Abiraterone acetate ) in combination with Prednisone ( a steroid ) to treat patients with late-stage ( metastatic ) castration-resistant ... read article

Zytiga for treatment of metastatic castration-resistant prostate cancer in patients who have received prior chemotherapy containing Docetaxel

The FDA ( Food and Drug Administration ) has approved Zytiga ( Abiraterone acetate ), an oral, once-daily medication for use in combination with Prednisone for the treatment of men with metastatic cas ... read article

Abiraterone improves survival in metastatic castration-resistant prostate cancer

Patients with metastatic castration-resistant prostate cancer who have progressed after chemotherapy live significantly longer if treated with the drug Abiraterone ( Zytiga )compared to placebo. Pat ... read article

Focus

New indication for Eylea in EU: treatment of visual impairment due to macular edema secondary to central retinal vein occlusion

Bayer HealthCare has announced that Eylea ( Aflibercept solution for injection ) has been approved by the European Commission ( EC ) for the treatment of visual impairment due to macular edema seconda ... read article

Ibrutinib shows efficacy as treatment for chronic lymphocytic leukemia and mantle cell lymphoma

Two clinical studies published in the New England Journal of Medicine ( NEJM ) suggest that the novel agent Ibrutinib shows real potential as a safe, effective, targeted treatment for adults with chro ... read article

Olmesartan Medoxomil can cause sprue-like enteropathy

FDA ( Food and Drug Administration ) has warned that the blood pressure drug Olmesartan Medoxomil ( marketed as Benicar, Benicar HCT, Azor, Tribenzor, and generics ) can cause intestinal problems know ... read article

Barrett's esophagus: Acetylsalicylic acid may fight cancer by slowing DNA damage

Aspirin ( Acetylsalicylic acid ) is known to lower risk for some cancers, and a new study led by a UC San Francisco researcher, Carlo Maley, points to a possible explanation, with the discovery that A ... read article

Metastatic or unresectable melanoma: FDA approves Tafinlar and Mekinist

The Food and Drug Administration ( FDA ) has approved two new drugs, Tafinlar ( Dabrafenib ) and Mekinist ( Trametinib ), for patients with advanced ( metastatic ) or unresectable melanoma, the most d ... read article

Giant cell tumor of the bone: FDA approves Xgeva

The Food and Drug Administration ( FDA ) has expanded the use of Xgeva ( Denosumab ) to treat adults and some adolescents with giant cell tumor of the bone ( GCTB ), a rare and usually non-cancerous t ... read article

Riociguat has demonstrated significant and sustained improvements in 6MWD and WHO functional class in patients with pulmonary arterial hypertension

Data from the interim analysis of the on-going PATENT-2 trial with Riociguat, the open-label long-term extension of the pivotal Phase III study PATENT-1, were presented at the American Thoracic Societ ... read article

Canagliflozin, a SGLT2 inhibitor, for the treatment of adults with type 2 diabetes

Janssen Pharmaceuticals has announced the FDA ( Food and Drug Administration ) has approved Invokana ( Canagliflozin ) for the treatment of adults with type 2 diabetes. Invokana is the first in a new ... read article